MEDPAL AI is trading 5.37% down at £6.70 after investors reacted to fresh equity dilution following the eMARx acquisition and a new executive option award.
- The company announced 40,000,000 options for its chief executive, representing approximately 5% of issued share capital.
- 1,075,872 new shares were admitted on September 9.
- The decline follows a sharp multi-session rally, suggesting profit-taking amplified dilution concerns.